Contribution of the WHHL rabbit, an animal model of familial hypercholesterolemia, to elucidation of the anti-atherosclerotic effects of statins

Atherosclerosis

Volumn 231, Issue 1, 2013, Pages 39-47

  Shiomi, Masashi ^a   Koike, Tomonari ^a   Ito, Takashi ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti atherosclerotic effects; Coronary atherosclerosis; Hypolipidemic effects; Plaque stabilization; Species differences; Statin; WHHL rabbit

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIOXIDANT; ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; COLCHICINE; COLESTYRAMINE; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MATRIX METALLOPROTEINASE; MEVALONIC ACID; MEVINOLIN; OMEGA 3 FATTY ACID; PITAVASTATIN; PRAVASTATIN; PROBUCOL; SQUALENE SYNTHASE INHIBITOR; THROMBOPLASTIN; UBIQUINONE;

ANTIOXIDANT ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; COMPETITIVE INHIBITION; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFECT; DRUG MECHANISM; FAMILIAL HYPERCHOLESTEROLEMIA; FOAM CELL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; IN VIVO STUDY; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPOPROTEIN METABOLISM; MACROPHAGE; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; REVIEW; SMOOTH MUSCLE FIBER; SPECIES DIFFERENCE; WATANABE HERITABLE HYPERLIPIDEMIC RABBIT;

ANTI-ATHEROSCLEROTIC EFFECTS; CORONARY ATHEROSCLEROSIS; HYPOLIPIDEMIC EFFECTS; PLAQUE STABILIZATION; SPECIES DIFFERENCES; STATIN; WHHL RABBIT;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; CHOLESTEROL; DISEASE MODELS, ANIMAL; FOAM CELLS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPERLIPOPROTEINEMIA TYPE II; MACROPHAGES; PLAQUE, ATHEROSCLEROTIC; RABBITS; TUNICA INTIMA;

EID: 84885401447     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.08.030     Document Type: Review

References (69)

1. Jukema J.W., Cannon C.P., de Craen A.J., Westendorp R.G., Trompet S. The controversies of statin therapy: weighing the evidence. JAm Coll Cardiol 2012, 60:875-881.
2. Shiomi M., Ito T. The Watanabe heritable hyperlipidemic (WHHL) rabbit, its characteristics and history of development: a tribute to the late Dr. Yoshio Watanabe. Atherosclerosis 2009, 207:1-7.
3. Endo A., Kuroda A., Tsujita Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by penicillium citrinum. JAntibiot (Tokyo) 1976, 29:1346-1348.
4. Goldstein J.L., Brown M.S. Binding and degradation of low density lipoproteins by cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia. JBiol Chem 1974, 249:5153-5162.
5. Watanabe Y. Serial inbreeding of rabbits with hereditary hyperlipidemia (WHHL-rabbit). Atherosclerosis 1980, 36:261-268.
6. Tanzawa K., Shimada Y., Kuroda M., Tsujita Y., Arai M., Watanabe Y. WHHL-rabbit: a low density lipoprotein receptor-deficient animal model for familial hypercholesterolemia. FEBS Lett 1980, 118:81-84.
7. Kita T., Brown M.S., Watanabe Y., Goldstein J.L. Deficiency of low density lipoprotein receptors in liver and adrenal gland of the WHHL rabbit, an animal model of familial hypercholesterolemia. Proc Natl Acad Sci U S A 1981, 78:2268-2272.
8. Yamamoto T., Bishop R.W., Brown M.S., Goldstein J.L., Russell D.W. Deletion in cysteine-rich region of LDL receptor impedes transport to cell surface in WHHL rabbit. Science 1986, 232:1230-1237.
9. Kozarsky K.F., Bonen D.K., Giannoni F., Funahashi T., Wilson J.M., Davidson N.O. Hepatic expression of the catalytic subunit of the apolipoprotein B mRNA editing enzyme (apobec-1) ameliorates hypercholesterolemia in LDL receptor-deficient rabbits. Hum Gene Ther 1996, 7:943-957.
10. Son Y.C., Zilversmit D.B. Increased lipid transfer activities in hyperlipidemic rabbit plasma. Arterioscler Thromb Vasc Biol 1986, 6(3):345-351.
11. Shiomi M., Ito T., Tsukada T., Tsujita Y., Horikoshi H. Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows synergistic effect on atherosclerosis of WHHL rabbits. Atherosclerosis 1999, 142:345-353.
12. Watanabe Y., Ito T., Shiomi M. The effect of selective breeding on the development of coronary atherosclerosis in WHHL rabbits, an animal model for familial hypercholesterolemia. Atherosclerosis 1985, 56:71-79.
13. Shiomi M., Ito T., Shiraishi M., Watanabe Y. Inheritability of atherosclerosis and the role of lipoproteins as risk factors in the development of atherosclerosis in WHHL rabbits: risk factors related to coronary atherosclerosis are different from those related to aortic atherosclerosis. Atherosclerosis 1992, 96:43-52.
14. Shiomi M., Ito T., Yamada S., Kawashima S., Fan J. Development of an animal model for spontaneous myocardial infarction (WHHLMI rabbit). Arterioscler Thromb Vasc Biol 2003, 23:1239-1244.
15. Endo A., Tsujita Y., Kuroda M., Tanzawa K. Effects of ML-236B on cholesterol metabolism in mice and rats: lack of hypocholesterolemic activity in normal animals. Biochim Biophys Acta 1979, 575:266-276.
16. Endo A. The discovery and development of HMG-CoA reductase inhibitors. JLipid Res 1992, 33:1569-1582.
17. Tsujita Y., Kuroda M., Shimada Y., et al. CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue selective inhibition of sterol synthesis and hypolipidemic effects on various animal species. Biochim Biophys Acta 1986, 877:50-60.
18. Shiomi M., Koike T., Ishida T. Genetically modified animal models for lipoprotein research. Lipoproteins - role in health and diseases 2012, 533-560. Intechopen.Com. S. Frank, G. Kostner (Eds.).
19. Nakamuta M., Oka K., Krushkal J., et al. Alternative mRNA splicing and differential promoter utilization determine tissue-specific expression of the apolipoprotein B mRNA-editing protein (Apobec1) gene in mice. Structure and evolution of Apobec1 and related nucleoside/nucleotide deaminases. JBiol Chem 1995, 270:13042-13056.
20. Agellon L.B., Walsh A., Hayek T., et al. Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice. JBiol Chem 1991, 266:10796-10801.
21. Ishibashi S., Brown M.S., Goldstein J.L., Gerard R.D., Hammer R.E., Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. JClin Invest 1993, 92:883-893.
22. Sanan D.A., Newland D.L., Tao R., et al. Low density lipoprotein receptor-negative mice expressing human apolipoprotein B-100 develop complex atherosclerotic lesions on a chow diet: no accentuation by apolipoprotein(a). Proc Natl Acad Sci U S A 1998, 95:4544-4549.
23. Mahley R.W., Ji Z.S. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. JLipid Res 1999, 40:1-16.
24. Li X., Catalina F., Grundy S.M., Patel S. Method to measure apolipoprotein B-48 and B-100 secretion rates in an individual mouse: evidence for a very rapid turnover of VLDL and preferential removal of B-48- relative to B-100-containing lipoproteins. JLipid Res 1966, 37:210-220.
25. Havel R.J., Kita T., Kotite L., et al. Concentration and composition of lipoproteins in blood plasma of the WHHL rabbit. An animal model of human familial hypercholesterolemia. Arteriosclerosis 1982, 2:467-474.
26. Watanabe Y., Ito T., Saeki M., et al. Hypolipidemic effects of CS-500 (ML-236B) in WHHL-Rabbit, a heritable animal model for hyperlipidemia. Atherosclerosis 1981, 38:27-31.
27. Shiomi M., Ito T. Pravastatin sodium, a competitive inhibitor of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase, decreases the cholesterol content of newly secreted very-low-density lipoprotein in Watanabe heritable hyperlipidemic rabbits. Metabolism 1994, 43:559-564.
28. Kurokawa J., Hayashi K., Toyota Y., Shingu T., Shiomi M., Kajiyama G. High dose of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, lowers plasma cholesterol levels in homozygous Watanabe-heritable hyperlipidemic rabbits. Biochim Biophys Acta 1995, 1259:99-104.
29. Suzuki H., Yamazaki H., Aoki T., et al. Lipid lowering and antiatherosclerotic effect of NK 104, a potent 3-Hydroxy 3-methylglutaryl coenzyme A reductase inhibitor, in Watanabe heritable hyperlipidemic rabbits. Arzneim Forsh/Drug Res 2000, 50:995-1003.
30. Kume N., Kita T., Mikami A., et al. Induction of mRNA for low-density lipoprotein receptor in heterozygous Watanabe heritable hyperlipidemic rabbits treated with CS-514 (Pravastatin) and cholestyramine. Circulation 1989, 79:1084-1090.
31. Ma P.T.S., Gil G., Sudhof T.C., Billheimer D.W., Goldstein J.L., Brown M.S. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc Natl Acad Sci U S A 1986, 83:8370-8374.
32. Kovanen P.T., Bilheimer D.W., Goldstein J.L., Jaramillo J.J., Brown M.S. Regulatory role for hepatic low density lipoprotein receptors invivo in the dog. Proc Natl Aced Sci U S A 1981, 78:1194-1198.
33. Schneider W.J., Brown M.S., Goldstein J.L. Kinetic defects in the processing of the low density lipoprotein receptor in fibroblasts from WHHL rabbits and a family with familial hypercholesterolemia. Mol Biol Med 1983, 1:353-367.
34. Shimada Y., Tanzawa K., Kuroda M., et al. Biochemical characterization of skin fibroblasts derived from WHHL-rabbit, a notable animal model for familial hypercholesterolemia. Eur J Biochem 1981, 118:557-564.
35. Krichevsky D., Tepper S.A., Klurfeld D.M. Influence of mevinolin on experimental atherosclerosis in rabbits. Pharmacol Res Commun 1981, 13:921-926.
36. Nguyen L.B., Shefer S., Salen G., Tint G.S., Ruiz F., Bullock J. Mechanisms for cholesterol homeostasis in rat jejunal mucosa: effects of cholesterol, sitosterol, and lovastatin. JLipid Res 2001, 42:195-200.
37. Watanabe Y., Ito T., Shiomi M., et al. Preventive effect of pravastatin sodium, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on coronary atherosclerosis and xanthoma in WHHL rabbits. Biochim Biophys Acta 1988, 960:294-302.
38. Kita T., Nagano Y., Yokode M., et al. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci U S A 1987, 84:5928-5931.
39. Carew T.E., Schwenke D.C., Steinberg D. Antiatherogenic effect of probucol unrelated to its hypercholesterolemic effect: evidence that antioxidants invivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbits. Proc Natl Acad Sci U S A 1987, 84:7725-7729.
40. Shiomi M., Ito T. Effects of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits. Br J Pharmacol 1999, 126:961-968.
41. Suzuki H., Kobayashi H., Sato F., Yonemitsu Y., Nakashima Y., Sueishi K. Plaque-stabilizing effect of pitavastatin in Watanabe heritable hyperlipidemic (WHHL) rabbits. JAtheroscler Thromb 2003, 10:109-116.
42. Worthley S.G., Helft G., Corti R., et al. Statin therapy alone and in combination with an acyl-CoA:cholesterol O-acyltransferase inhibitor on experimental atheroscelrosis. Pathophysiol Haemaost Thromb 2007/2008, 36:9-17.
43. Shiomi M., Ito T., Watanabe Y., et al. Suppression of established atherosclerosis and xanthomas in mature WHHL rabbits by keeping their serum cholesterol levels extremely low. Effect of pravastatin sodium in combination with cholestyramine. Atherosclerosis 1990, 83:69-80.
44. Shiomi M., Ito T., Tsukada T., Yata T., Ueda M. Cell compositions of coronary and aortic atherosclerotic lesions in WHHL rabbits differ: an immunohistochemical study. Arterioscler Thromb Vasc Biol 1994, 14:931-937.
45. Shiomi M., Ito T., Tsukada T., et al. Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques: effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits. Arterioscler Theromb Vasc Biol 1995, 15:1938-1944.
46. Shiomi M., Ito T., Hirouchi Y., Enomoto M. Fibromuscular cap composition is important for the stability of established atherosclerotic plaques in mature WHHL rabbits treated with statins. Atherosclerosis 2001, 157(1):75-84.
47. Shiomi M., Yamada S., Ito T. Atheroma stabilizing effects of simvastatin due to depression of macrophages or lipid accumulation in the atheromatous plaques of coronary atherosclerosis-prone WHHL rabbits. Atherosclerosis 2005, 178:287-294.
48. Aikawa M., Rabkin E., Sugiyama S., et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor invivo and invitro. Circulation 2001, 103:276-283.
49. Fukumoto Y., Libby P., Rabkin E., et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe heritable hyperlipidemic rabbits. Circulation 2001, 103:993-999.
50. Brown B.G., Zhao X., Sacco D., Albers J.J. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993, 87:1781-1791.
51. Jukema J.W., Bruschke A.V., van Boven A.J., et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995, 91:2528-2540.
52. 18F-FDG PET for monitoring the therapeutic effect of antiinflammatory drugs on stabilization of vulnerable atherosclerotic plaques. JNucl Med 2006, 47:1845-1850.
53. Iwata A., Miura S., Zhang B., et al. Antiatherogenic effects of newly developed apolipoprotein A-I mimetic peptide/phospholipid complexes against aortic plaque burden in Watanabe-heritable hyperlipidemic rabbits. Atherosclerosis 2011, 218:300-307.
54. Liao J.K. Isoprenoids as mediators of the biological effects of statins. JClin Invest 2002, 110:285-288.
55. Rosenson R.S., Tangney C.C. Antiatherothrombotic properties of statins. Jm Assoc Med Assoc 1998, 279:1643-1650.
56. Kroon A.A., Stalenhoef A.F.H., Buikema H., et al. The effect of cholesterol reduction on the endothelial function and progression of atherosclerosis in WHHL rabbits. Atherosclerosis 1993, 103:221-230.
57. Williams J.K., Sukhova G.K., Herrington D.M., Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. JAm Coll Cardiol 1998, 31:684-691.
58. Mital S., Zhang X., Zhao G., et al. Simvastatin upregulates coronary vascular endothelial nitric oxide production in conscious dogs. Am J Physiol Heart Circ Physiol 2000, 279:H2649-H2657.
59. Balakumar P., Kathuria S., Taneja G., Kalra S., Mahadevan N. Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins?. JMol Cell Cardiol 2012, 52:83-92.
60. Aikawa M., Sugiyama S., Hill C.C., et al. Lipid lowering reduces oxidative stress and endothelial cell activation in rabbit atheroma. Circulation 2002, 106:1390-1396.
61. Aikawa M., Rabkin E., Okada Y., et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation 1998, 97:2433-2444.
62. Aikawa M., Voglic S.J., Sugiyama S., et al. Dietary lipid lowering reduces tissue factor expression in rabbit atheroma. Circulation 1999, 100:1215-1222.
63. Leung W.H., Lau C.P., Wong C.K. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet 1993, 341:1496-1500.
64. Shiomi M., Yamada S., Amano Y., Nishimoto T., Ito T. Lapaquistat acetate, a squalene synthesis inhibitor, changes macrophage/lipid-rich coronary plaques of hypercholesterolemic rabbits into fibrous lesions. Br J Pharmacol 2008, 154:949-957.
65. Nègre-Aminou P., van Vliet A.K., van Erck M., van Thiel G.C., van Leeuwen R.E., Cohen L.H. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. Biochim Biophys Acta 1997, 1345:259-268.
66. Shiomi M., Ito T., Tsukada T., Shiraishi M., Yata T. Effect of fluvastatin sodium on the smooth muscle cells in atherosclerotic plaques: invivo study using low-density lipoprotein receptor deficient Watanabe heritable hyperlipidemic (WHHL) rabbits. Arzneim Forsh/Drug Res 1998, 48:680-685.
67. Proctor S.D., Mamo C.L. Intimal retention of cholesterol derived from apolipoprotein B100- and apolipoprotein B48-containing lipoproteins in carotid. Arterioscler Thromb Vasc Biol 2003, 23:1595-1600.
68. Takahashi S., Ito T., Zenimaru Y., et al. Species differences of macrophage very low-density-lipoprotein (VLDL) receptor protein expression. Biochem Biophys Res Commun 2011, 407:656-662.
69. Sever P.S., Dahlöf B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149-1158.